Moreover, therapeutic efficacy is clinically monitored by reductions in serum PSA (prostate specific antigen), as expression of PSA is dependent on AR activity in prostatic cells and correlates with tumour burden (Catalona and Loeb, 2005). This evidence concerns the gene AR and neoplasm.